ACM Research (ACMR) Q2 2026 Earnings Call Transcript

ACM Research reported Q2 revenue of $292.9M (+36% YoY) and shipments of $281.5M (+36.4% YoY), with non-GAAP diluted EPS of $0.61 (vs. $0.55). Gross margin fell to 46.0% from 48.7%, but non-GAAP operating income rose to $56.3M (vs. $41.5M) and operating margin improved to 19.2%. The company raised 2026 revenue guidance to $1.125B–$1.175B (implying 25%–30% YoY growth) and ended the quarter with $1.0B net cash (including about $300M in the U.S.), alongside a 105% YoY jump in first-half orders.

Analysis

The market should treat this as an order-conversion story more than a simple earnings beat. The real upside is that ACMR is moving from a one-product China tool vendor to a multi-platform wet process supplier with global qualification optionality; that can support a higher multiple if the new platforms convert from evaluation to repeat orders. The first derivative is cleaner than the second: the stock can keep working over the next 1-2 quarters if shipments accelerate into backlog, but the durable re-rate depends on whether the new products show true production pull-through rather than pilot noise.

The hidden risk is working capital. High inventory and stretched component lead times usually mean management is front-loading supply to protect revenue, which is fine until customer acceptance slips; then cash conversion can deteriorate quickly and the market starts questioning the quality of growth. The second-order winner is the broader advanced packaging ecosystem in Asia, especially customers building capacity outside Mainland China, while incumbent wet-process suppliers face incremental share pressure if ACMR’s panel-level plating wins become sticky. The first thing that would falsify the bull case is any sign that Q3/Q4 shipments fail to step up despite the raised full-year view, or that gross margin drifts toward the bottom of the stated band because new-platform ramps are less profitable than legacy tools.

Consensus is probably underestimating how much of 2027 is already being pulled forward by 2026 qualifications, but also overestimating how linear that path will be. The big gap in the bull narrative is visibility into backlog quality: orders are up sharply, yet the conversion rate to revenue and the mix between China and ex-China matters more than the headline order growth. If the Oregon demo center and overseas installs lead to a few marquee wins, the stock can sustain a premium; if not, this becomes another cyclical equipment name with a good quarter and an expensive forward multiple.

Key Decisions for Investors

• Long ACMR on pullbacks over the next 1-3 weeks; thesis is backlog conversion and 2027 qualification optionality. Risk/reward is favorable if the market starts pricing the new platforms as recurring revenue rather than one-off eval wins.
• Use a tight hedge: long ACMR / short SOXX for 1-3 month catalyst exposure. This isolates idiosyncratic upside from the order book while reducing beta if semicap multiples compress.
• Set a tactical exit trigger if revenue/shipments fail to accelerate sequentially in the next reported quarter or if gross margin slips below the low-40% range; that would imply mix and supply-chain issues are overwhelming demand growth.
• Watch-list, not buy, if the stock re-rates hard before backlog is disclosed: wait for the September/October backlog update to confirm order quality before adding aggressively.
• For more aggressive exposure, consider a call spread on ACMR into the next 2-4 months only if the shares have not already priced in the raised guide; otherwise the better trade is equity with a hard stop because the key risk is timing, not terminal demand.